Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis

PI3Kδ inhibitors are active in patients with lymphoid neoplasms and a first series of them have been approved for the treatment of multiple types of B-cell lymphoid tumors, including marginal zone lymphoma (MZL). The identification of the mechanisms underlying either primary or secondary resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Arribas, Alberto J., Napoli, Sara, Cascione, Luciano, Sartori, Giulio, Barnabei, Laura, Gaudio, Eugenio, Tarantelli, Chiara, Mensah, Afua Adjeiwaa, Spriano, Filippo, Zucchetto, Antonella, Rossi, Francesca M., Rinaldi, Andrea, de Moura, Manuel Castro, Jovic, Sandra, Bordone-Pittau, Roberta, Di Veroli, Alessandra, Stathis, Anastasios, Cruciani, Gabriele, Stussi, Georg, Gattei, Valter, Brown, Jennifer R., Esteller, Manel, Zucca, Emanuele, Rossi, Davide, Bertoni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Non-Hodgkin Lymphoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614536/
https://www.ncbi.nlm.nih.gov/pubmed/35484662
http://dx.doi.org/10.3324/haematol.2021.279957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614536/
https://www.ncbi.nlm.nih.gov/pubmed/35484662
http://dx.doi.org/10.3324/haematol.2021.279957

Ejemplares similares